专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06399374B1 Converting diploidy to haploidy for genetic diagnosis 失效
标题翻译：将二倍体转化为单倍体用于遗传诊断
公开(公告)号：US06399374B1
公开(公告)日：2002-06-04
申请号：US09461047
申请日：1999-12-15
申请人： Bert Vogelstein , Kenneth W. Kinzler , Hai Yan , Nicholas Papadopoulos
发明人： Bert Vogelstein , Kenneth W. Kinzler , Hai Yan , Nicholas Papadopoulos
IPC分类号： C12N512
CPC分类号： C12N5/166 , C12Q1/6886 , C12Q2600/156
摘要： Detection of mutations associated with hereditary diseases is complicated by the diploid nature of human cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.
摘要翻译：与遗传性疾病相关的突变的检测由于人类细胞的二倍体性质而复杂化。存在于一个等位基因中的突变通常被其他等位基因的野生型序列掩蔽。可以从单次融合产生的体细胞杂交体内的每个染色体分离个体等位基因。来自杂种的核酸可以以明确的方式分析突变。这种方法被用于检测先前不符合遗传诊断的两种致癌突变。研究的家庭之一，Warthin Family G，是生物医学文献中描述的第一个遗传性结肠癌综合症患者。

2. 发明申请

US20060030529A1 Use of VEGF inhibitors for treatment of eye disorders 有权
公开(公告)号：US20060030529A1
公开(公告)日：2006-02-09
申请号：US11218234
申请日：2005-09-01
申请人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos , James Fandl , Thomas Daly
发明人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos , James Fandl , Thomas Daly
IPC分类号： A61K38/17
CPC分类号： C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.

3. 发明申请

US20050163798A1 Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof 有权
公开(公告)号：US20050163798A1
公开(公告)日：2005-07-28
申请号：US11016097
申请日：2004-12-17
申请人： Nicholas Papadopoulos , Samuel Davis , George Yancopoulos
发明人： Nicholas Papadopoulos , Samuel Davis , George Yancopoulos
IPC分类号： A61K38/00 , C07K14/71 , C07H21/04 , A61K39/00
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.

4. 发明申请

US20070280945A1 High affinity antibodies to human IL-6 receptor 有权
标题翻译：对人IL-6受体的高亲和力抗体
公开(公告)号：US20070280945A1
公开(公告)日：2007-12-06
申请号：US11809482
申请日：2007-06-01
申请人： Sean Stevens , Tammy Huang , Joel Martin , Jeanette Fairhurst , Ashique Rafique , Eric Smith , Kevin Pobursky , Nicholas Papadopoulos , James Fandl , Gang Chen , Margaret Karow
发明人： Sean Stevens , Tammy Huang , Joel Martin , Jeanette Fairhurst , Ashique Rafique , Eric Smith , Kevin Pobursky , Nicholas Papadopoulos , James Fandl , Gang Chen , Margaret Karow
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/24 , C12N5/06
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
摘要翻译：结合人IL-6受体（hIL-6R）的人抗体或抗原结合片段，其具有约500pM以下的K D D以及用IC < 50微米或更小。在优选的实施方案中，抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。

5. 发明授权

US07534604B2 Fusion polypeptides capable of activating receptors 有权
标题翻译：能够激活受体的融合多肽
公开(公告)号：US07534604B2
公开(公告)日：2009-05-19
申请号：US11035599
申请日：2005-01-14
申请人： James P. Fandl , Gang Chen , Nicholas Papadopoulos , Thomas H. Aldrich
发明人： James P. Fandl , Gang Chen , Nicholas Papadopoulos , Thomas H. Aldrich
IPC分类号： C12P21/04 , C12N5/00 , C07H21/04
CPC分类号： C07K16/2863 , C07H21/04 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C07K2317/75 , C07K2319/30
摘要： A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
摘要翻译：包含（A）x-M-（A'）y的融合多肽，其中A和A'是能够结合靶受体的多肽。本发明的融合多肽形成激活靶受体的多聚体蛋白。 A和A'可以各自为衍生自靶受体（例如相同或不同ScFv片段）的特异性抗体的抗体或片段，和/或能够结合靶蛋白质的配体或配体片段或衍生物，M为多聚化组分，X和Y独立地为1-10之间的数。

6. 发明申请

US20080181893A1 Therapeutic methods for treating vascular eye disorders with DII4 antagonists 审中-公开
标题翻译：用DII4拮抗剂治疗血管性眼病的治疗方法
公开(公告)号：US20080181893A1
公开(公告)日：2008-07-31
申请号：US11890741
申请日：2007-08-07
申请人： Ivan B. Lobov , Nicholas Papadopoulos , Stanley J. Wiegand
发明人： Ivan B. Lobov , Nicholas Papadopoulos , Stanley J. Wiegand
IPC分类号： A61K39/395 , A61P27/02
CPC分类号： C07K16/2863 , A61K38/1709 , A61K2039/505 , C07K2317/76 , C07K2319/30
摘要： A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (Dll4) activity to a subject in need thereof. In one embodiment, the agent is an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor. The method of the invention is useful for treating eye disorders such as ischemic retinopathy, diabetic retinopathy, age related macular degeneration, corneal neovascularization, neovascular glaucoma, or retinopathy of prematurity. The method is also useful or treating ischemic or vascular disorders such as ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension.
摘要翻译：一种通过向有需要的受试者施用能够抑制人类δ样配体4（Dll4）活性的试剂来治疗缺血性或血管性疾病的治疗方法。在一个实施方案中，该试剂是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段。本发明的方法可用于治疗眼部疾病如缺血性视网膜病变，糖尿病性视网膜病变，年龄相关性黄斑变性，角膜新生血管形成，新生血管性青光眼或早产儿视网膜病变。该方法还可用于治疗缺血性或血管性疾病，例如缺血性损伤，脑缺血，心脏缺血，影响肢体和其他器官或组织的缺血状况，动静脉畸形，伤口愈合，器官或组织移植，胎盘功能不全，动脉狭窄和闭塞，动脉粥样硬化和全身或肺动脉高压。

7. 发明申请

US20050260203A1 Use of VEGF inhibitors for treatment of eye disorders 有权
标题翻译：使用VEGF抑制剂治疗眼睛疾病
公开(公告)号：US20050260203A1
公开(公告)日：2005-11-24
申请号：US11089803
申请日：2005-03-25
申请人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos , James Fandl , Thomas Daly
发明人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos , James Fandl , Thomas Daly
IPC分类号： A61K38/00 , A61K38/17 , A61K39/395 , C07K14/47 , C07K14/71
CPC分类号： C07K14/71 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译：公开了具有改善的药物动力学和改善的组织穿透的修饰的嵌合多肽，其可用于治疗眼睛疾病，包括年龄相关性黄斑变性和糖尿病性视网膜病变。

8. 发明申请

US20050175610A1 Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof 有权
标题翻译：具有改善的药代动力学性质的修饰的嵌合多肽及其制备和使用方法
公开(公告)号：US20050175610A1
公开(公告)日：2005-08-11
申请号：US10988243
申请日：2004-11-12
申请人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos
发明人： Stanley Wiegand , Nicholas Papadopoulos , George Yancopoulos
IPC分类号： A61K38/00 , C07K14/71 , A61K39/395 , A61K38/17
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译：公开了具有改善的药代动力学的修饰的嵌合多肽可用于治疗眼睛疾病，包括年龄相关性黄斑变性和糖尿病性视网膜病变。

9. 发明申请

US20050043236A1 VEGF traps and therapeutic uses thereof 有权
标题翻译： VEGF陷阱及其治疗用途
公开(公告)号：US20050043236A1
公开(公告)日：2005-02-24
申请号：US10880021
申请日：2004-06-29
申请人： Thomas Daly , James Fandl , Nicholas Papadopoulos
发明人： Thomas Daly , James Fandl , Nicholas Papadopoulos
IPC分类号： A61K38/00 , C07K14/71 , A61K38/17 , C07H21/04
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00
摘要： Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
摘要翻译：能够结合血管内皮生长因子（VEGF）的核酸分子和多聚体蛋白质。公开了可用于治疗VEGF相关病症和疾病的VEGF陷阱，其专门用于局部给予特定器官，组织和/或细胞。

10. 发明授权

US07303746B2 Methods of treating eye disorders with modified chimeric polypeptides 有权
标题翻译：用修饰的嵌合多肽治疗眼部疾病的方法
公开(公告)号：US07303746B2
公开(公告)日：2007-12-04
申请号：US10988243
申请日：2004-11-12
申请人： Stanley J. Wiegand , Nicholas Papadopoulos , George D. Yancopoulos
发明人： Stanley J. Wiegand , Nicholas Papadopoulos , George D. Yancopoulos
IPC分类号： A61K38/18 , C07K14/71 , C12N15/62
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/00
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
摘要翻译：公开了具有改善的药代动力学的修饰的嵌合多肽可用于治疗眼睛疾病，包括年龄相关性黄斑变性和糖尿病性视网膜病变。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式